Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
US10695426B2 · kind B2 · utility
1Cited by
21References
17Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 24, 2015 |
| Grant date | Jun 30, 2020 |
| Priority date | — |
| Expiry date | Oct 25, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and an Anaplastic Lymphoma Kinase (ALK) inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that test positive for ALK, PD-L 1, or both ALK and PD-L 1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.